Haleon (HLN) Hisse Özeti
Haleon plc, bağlı ortaklıklarıyla birlikte Kuzey Amerika, Avrupa, Orta Doğu, Afrika, Latin Amerika ve Asya Pasifik'te çeşitli tüketici sağlığı ürünlerinin araştırılması, geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 6/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 3/6 |
Ödüller
Risk Analizi
HLN Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Haleon plc Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | UK£3.35 |
| 52 Haftanın En Yüksek Seviyesi | UK£4.16 |
| 52 Haftanın En Düşük Seviyesi | UK£2.74 |
| Beta | 0.25 |
| 1 Aylık Değişim | -8.32% |
| 3 Aylık Değişim | 0.24% |
| 1 Yıllık Değişim | -8.27% |
| 3 Yıllık Değişim | 4.58% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | 8.58% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 01
HLN: Lower Forward P E Assumptions Will Pressure Future Share Price
Haleon’s analyst price target has been trimmed by £0.10 to £3.15, as analysts factor in a slightly lower assumed future P/E, alongside recent Street moves that have reduced targets and, in one case, shifted the stock to a Neutral stance. Analyst Commentary Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and reassessing risk around valuation, execution and future growth assumptions.Anlatı Güncellemesi • Jun 17
HLN: Cautious Ratings And Execution Progress Will Guide Future Share Price
Haleon’s latest Narrative Update reflects a modest reset in analyst expectations, with the average price target easing in line with recent cuts to £4.30 and £3.65 from major banks as analysts factor in slightly revised assumptions on revenue growth, profit margin and future P/E multiples. Analyst Commentary on Haleon stock Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and, in at least one case, moving to a more neutral stance on the shares.Recent updates
Anlatı Güncellemesi • Jul 01
HLN: Lower Forward P E Assumptions Will Pressure Future Share Price
Haleon’s analyst price target has been trimmed by £0.10 to £3.15, as analysts factor in a slightly lower assumed future P/E, alongside recent Street moves that have reduced targets and, in one case, shifted the stock to a Neutral stance. Analyst Commentary Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and reassessing risk around valuation, execution and future growth assumptions.Anlatı Güncellemesi • Jun 17
HLN: Cautious Ratings And Execution Progress Will Guide Future Share Price
Haleon’s latest Narrative Update reflects a modest reset in analyst expectations, with the average price target easing in line with recent cuts to £4.30 and £3.65 from major banks as analysts factor in slightly revised assumptions on revenue growth, profit margin and future P/E multiples. Analyst Commentary on Haleon stock Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and, in at least one case, moving to a more neutral stance on the shares.Anlatı Güncellemesi • Jun 01
HLN: Mixed Rating Revisions And Execution Risks Will Shape Future Upside
Narrative Update The analyst price target for Haleon has been trimmed by about £0.10 per share. This reflects slightly softer revenue growth assumptions, a higher discount rate, and a lower future P/E, partly offset by firmer profit margin expectations and a mix of recent target moves from Berenberg, Morgan Stanley, and Deutsche Bank.
Anlatı Güncellemesi • May 10
HLN: Cash Returns And China Expansion Will Support Future Premium Re Rating
Haleon's updated analyst price target of £5.12, which compares with prior targets in the £4.40 to £5.17 range, reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E as analysts reassess the stock following recent mixed target changes across the Street. Analyst Commentary Recent Street research on Haleon presents a mixed picture, but there are clear pockets of optimism as some bullish analysts fine tune their targets around current valuation frameworks.Anlatı Güncellemesi • Apr 22
HLN: Cash Returns And China Expansion Will Support Future Re Rating Potential
Narrative Update on Haleon Haleon's analyst price targets have shifted modestly higher, with recent moves such as Berenberg's adjustment to £5.12 from £5.10 and Morgan Stanley's move to £4.40 from £4.20, as analysts point to slightly stronger assumptions for revenue growth and profit margins, along with a marginally lower future P/E. Analyst Commentary Recent research points to a generally constructive tone around Haleon, with several bullish analysts adjusting price targets higher in the latest updates.Analiz Makalesi • Apr 09
If EPS Growth Is Important To You, Haleon (LON:HLN) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Anlatı Güncellemesi • Apr 07
HLN: Execution And Cash Returns Will Support Future Re Rating Potential
Haleon's analyst price targets have edged higher, with recent moves such as Berenberg's lift to £5.12 and Morgan Stanley's increase to £4.40. These changes reflect analysts' updated views on slightly stronger revenue growth and profit margin assumptions, alongside modestly adjusted future P/E expectations.Anlatı Güncellemesi • Mar 24
HLN: Execution And Cash Returns Will Support Future Re Rating Potential
Haleon's analyst price target has been nudged up from £5.10 to £5.12, reflecting analysts' updated assumptions for slightly higher revenue growth and profit margins, together with recent target increases and rating changes across several research houses. Analyst Commentary Recent Street research on Haleon has been active, with several bullish analysts adjusting their targets and ratings while one major European house turned more cautious.Anlatı Güncellemesi • Mar 10
HLN: Execution And New Operating Model Will Support Future Re Rating Potential
The analyst price target for Haleon has inched down from £5.17 to £5.10. This reflects a mix of recent research in which some analysts trimmed expectations on growth and valuation multiples, while others turned more positive on the shares overall.Anlatı Güncellemesi • Feb 23
HLN: Execution And Margin Delivery Concerns Will Limit Upside Potential
Our updated analyst price target for Haleon edges lower to £5.10. This reflects modest tweaks to growth and margin assumptions as analysts balance recent target cuts with upgrades, while keeping long term expectations for revenue, profitability and P/E broadly in line with prior views.Anlatı Güncellemesi • Feb 09
HLN: Sector Headwinds And Execution Risks Will Constrain Upside Potential
Narrative Update on Haleon The latest analyst price target for Haleon has been revised, reflecting Street research that highlights modestly lower revenue growth assumptions, slightly higher profit margin expectations, and updated sector views following recent upgrades and one downgrade. Analyst Commentary Recent Street research on Haleon has been mixed, with several firms updating their views in quick succession.Anlatı Güncellemesi • Jan 26
HLN: Portfolio Execution And New Operating Model Will Support Re Rating
The average analyst price target for Haleon has edged up to £5.17 from £5.10, as analysts cite slightly higher margin assumptions, a modest reset to revenue growth expectations, and supportive recent rating changes and target increases from several firms across the Street. Analyst Commentary Recent Street research on Haleon has been active, with both bullish and more cautious voices weighing in.Anlatı Güncellemesi • Jan 11
HLN: Modest Uplift In Outlook Will Balance Execution And Valuation Risks
Analysts have raised their Haleon price target by £0.10, from 507 GBp to 517 GBp. This change reflects updated assumptions for slightly higher revenue growth, a small adjustment to profit margins, and a modestly lower future P/E. Analyst Commentary The latest price target move to 517 GBp signals that at least one research house still sees room for upside in Haleon, but the change is relatively modest.Anlatı Güncellemesi • Dec 26
HLN: Rising Confidence In Earnings And Cash Generation Will Support Re Rating
Analysts have nudged their price target on Haleon higher to approximately £5.17 from about £5.07, citing stronger projected revenue growth and a modestly higher future valuation multiple, despite a slightly increased discount rate and marginally lower profit margin assumptions. Analyst Commentary Bullish analysts have reiterated a constructive stance on Haleon, underscored by a series of incremental price target increases that signal growing confidence in the company’s earnings trajectory and cash generation.Analiz Makalesi • Dec 20
Is Now The Time To Put Haleon (LON:HLN) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Anlatı Güncellemesi • Dec 12
HLN: Modest Price Objective Increase Will Highlight Balanced Outlook And Execution Risks
Analysts have modestly raised their fair value estimate for Haleon, reflecting a series of incremental price target increases to approximately 517 GBp. This change indicates growing confidence in the company’s accelerating revenue growth and resilient margins, despite a slightly higher discount rate. Analyst Commentary While the latest price target revisions for Haleon are modestly positive, some bearish analysts highlight that the incremental nature of these changes underscores lingering uncertainty around the company’s long term growth trajectory.Analiz Makalesi • Nov 14
Are Investors Undervaluing Haleon plc (LON:HLN) By 35%?
Key Insights The projected fair value for Haleon is UK£5.76 based on 2 Stage Free Cash Flow to Equity Current share...Analiz Makalesi • Oct 27
Earnings Not Telling The Story For Haleon plc (LON:HLN)
Haleon plc's ( LON:HLN ) price-to-earnings (or "P/E") ratio of 20.5x might make it look like a sell right now compared...Analiz Makalesi • Sep 15
Haleon (LON:HLN) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Yeni Anlatı • Mar 02
Sensodyne IND 20 And Cost Savings Will Strengthen Future Market Position
Haleon is driving growth through innovation and international expansion in emerging markets, enhancing market share and revenue.Hissedar Getirileri
| HLN | GB Pharmaceuticals | GB Pazar | |
|---|---|---|---|
| 7D | -8.5% | -3.4% | -0.7% |
| 1Y | -8.3% | 1.8% | 16.1% |
Getiri vs. Endüstri: HLN geçen yıl % 1.8 oranında getiri sağlayan UK Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: HLN geçen yıl % 16.1 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| HLN volatility | |
|---|---|
| HLN Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
İstikrarlı Hisse Senedi Fiyatı: HLN son 3 ayda UK piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: HLN 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1715 | 24,535 | Brian McNamara | www.haleon.com |
Haleon plc, bağlı şirketleriyle birlikte Kuzey Amerika, Avrupa, Orta Doğu, Afrika, Latin Amerika ve Asya-Pasifik bölgelerinde çeşitli tüketici sağlık ürünlerinin araştırma, geliştirme, üretim ve satış faaliyetlerini yürütmektedir. Şirket, Sensodyne, Polident, Parodontax ve Biotene markaları altında diş macunları, ağız gargaraları ve takma diş bakım ürünleri gibi ağız sağlığı ürünleri; Centrum, Emergen-C ve Caltrate markaları altında ise vitaminler, mineraller ve takviye ürünleri sunmaktadır. Ayrıca, solunum sorunları için Theraflu ve Flonase markaları altında burun damlaları ile soğuk algınlığı, grip ve alerji giderici ürünleri; ağrı kesici ürünler için Voltaren, Panadol ve Advil markaları; sindirim sağlığı ve diğer sorunlar için TUMS, ENO, ve Fenistil markaları altında sindirim sağlığı ve diğer sorunlara yönelik antasitler ve antihistaminik ürünler sunmaktadır.
Haleon plc Temel Bilgiler Özeti
| HLN temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | UK£29.49b |
| Kazançlar(TTM) | UK£1.62b |
| Gelir(TTM) | UK£11.15b |
18.2x
F/K Oranı2.6x
P/S OranıHLN aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| HLN gelir tablosu (TTM) | |
|---|---|
| Gelir | UK£11.15b |
| Gelir Maliyeti | UK£3.84b |
| Brüt Kâr | UK£7.31b |
| Diğer Giderler | UK£5.69b |
| Kazançlar | UK£1.62b |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 0.18 |
| Brüt Marj | 65.57% |
| Net Kâr Marjı | 14.55% |
| Borç/Özkaynak Oranı | 49.2% |
HLN uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
2.2%
Mevcut Temettü Verimi40%
Ödeme OranıHLN güvenilir bir temettü ödüyor mu?
HLN temettü geçmişine ve kıyaslamalara bakın| Haleon temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Aug 13 2026 |
| Temettü Ödeme Tarihi | Sep 17 2026 |
| Eski temettüye kadar geçen günler | 28 days |
| Temettü ödeme tarihine kadar geçen günler | 7 days |
HLN güvenilir bir temettü ödüyor mu?
HLN temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/09 07:35 |
| Gün Sonu Hisse Fiyatı | 2026/09/09 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Haleon plc 26 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Iain Simpson | Barclays |
| Warren Ackerman | Barclays |
| Bethan Davies | Berenberg |